Complement-targeted therapeutics.

摘要: The complement system is a central component of innate immunity and bridges the to adaptive immune response. However, it can also turn its destructive capabilities against host cells involved in numerous diseases pathological conditions. Modulation has been recognized as promising strategy drug discovery, large number therapeutic modalities have developed. successful marketing complement-targeted drugs proved be more difficult than initially expected, many strategies discontinued. US Food Drug Administration's approval first complement-specific drug, an antibody C5 (eculizumab; Soliris), March 2007, was long-awaited breakthrough field. Approval eculizumab validates target might facilitate clinical development other candidates.